News

Systemic Sclerosis in Pulmonary Arterial Hypertension Prognosis Aided Through Vascular Receptor Autoantibodies

A new study entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis” published in the October issue of American Journal of Respiratory and Critical Care Medicine reports that vascular antibodies can be prognostic biomarkers in Systemic Sclerosis (SSc) associated with pulmonary arterial…

Data on Systemic Sclerosis Drug Candidate To Be Presented at Rare Disease Roundtable

The chief executive officer of clinical stage biopharmaceutical company Corbus Pharmaceuticals Holdings, Yuval Cohen, Ph.D., is presenting an update on the company’s research, as well as revision of previous clinical developments regarding Corbus’s lead product candidate, Resunab, at the Leerink Partners Rare Disease Roundtable. The product candidate is being studied by the drug…

Previously PH-Tested Viagra Now Evaluated as Scleroderma Therapy

Having previously experimented with the use of Viagra (Sildenafil) as a possible therapy for Pulmonary arterial hypertension (PAH), researchers have now evaluated the use of the drug in treating Systemic Sclerosis (SSc) in patients. SSc or scleroderma, is a chronic connective tissue disease characterized by hardening of the skin. The…

Teva, Active Biotech Partner To Develop Laquinimod For Huntington’s Disease

Active Biotech, a Sweden-based biopharmaceutical company that is developing therapies for autoimmune diseases, inflammatory diseases, and cancers, recently announced that it is partnering with Teva Pharmaceutical Industries Ltd. to develop a new, experimental drug for treating Huntington’s disease. The two companies will work together to launch a new phase 2 clinical trial in…